Science

How a marker gets into the panel.

Rule-based, documented and repeatable. Every decision can be traced back to a source and a written rule.

The selection pipeline

Six steps, in this order.

The pipeline is reproducible code. When a source is updated, the panel can be rebuilt and every change is visible.

  1. Screen

    All genome-wide associations in the GWAS Catalog, filtered by a 984-term keyword list across 47 categories and P ≤ 5×10⁻⁸.

  2. Annotate

    ClinVar, Open Targets, gnomAD allele frequencies, Europe PMC citations, errata and retractions are joined to every variant.

  3. Grade

    Each association gets an evidence grade from Strong to Limited, using fixed thresholds rather than judgement.

  4. Ask: can you act on it?

    Traits a person cannot change, such as height or eye colour, are removed however well studied they are.

  5. Separate the medical

    Diagnostic, pharmacogenomic and disease-named findings are classified and kept out of lifestyle advice.

  6. Expert review

    Each recommendation is reviewed and signed off by a nutrition professional before any user sees it.

Layer 1 · Evidence grade

How strong is the science?

Strong

Replicated, highly significant and consistent in direction.

≥ 3 publications · P ≤ 10⁻²⁰

Moderate

Consistent across studies, or one very large study.

≥ 2 studies · or P ≤ 10⁻¹⁵, N ≥ 50,000

Emerging

A single genome-wide significant study. Shown in research views only.

1 study · P ≤ 5×10⁻⁸

Limited

Studies disagree on the direction of the effect. Not reported.

direction mixed · < 80 % agreement
Layer 2 · Actionability

Can a change in daily life move it?

Our nutrition reviewer pointed out that an earlier selection favoured traits that had been studied the most. We rebuilt the score so that modifiability multiplies the evidence instead of competing with it.

ClassWhat it meansExampleWeight
1Changes a measurable biomarkerVitamin D, homocysteine, LDL cholesterol× 1.00
2Changes behaviour or intakeCaffeine metabolism, bitter taste× 0.85
3Changes body compositionResponse to physical activity× 0.90
4Partially modifiableTraits with small lifestyle effects× 0.45
5Fixed or structuralHeight, hair colour, age at menopause× 0.10

Result: 525 variants in 445 genes, no fixed or structural traits, 194 graded Strong, 99 with documented gene × lifestyle interaction.

A scientist pipetting into test tubes
Safety class

Where wellness ends.

Every row carries a safety class and the reason it was assigned. The class decides what a user may ever see.

  • LifestyleReported normally, with its source.
  • BorderlineThe action is kept; disease names and risk figures are removed.
  • DiagnosticNever returned. These belong with a physician.
  • PharmacogenomicInformation for prescribers only.
  • RefusedThe market claims it; the evidence does not support it, and we say so.
The market we enter

We read 65 competitors before writing a line of product.

North America, Europe and Asia: websites, sample reports, validation papers and regulator lists.

48 / 65companies publish no marker list at all
6publish their panel in full
53 / 130published markers have no genome-wide evidence
525markers we will publish, each with its source
Sources

Public, citable databases.

GWAS Catalog

Genome-wide associations and study ancestry (EMBL-EBI / NHGRI).

ClinVar

Clinical significance, used to separate diagnostic variants from lifestyle variants.

Open Targets

Variant effect prediction, allele frequencies, credible sets and locus-to-gene scores.

Europe PMC

Citations, errata and retractions for every paper we rely on.

CPIC & ClinPGx

Drug–gene guidance, used to route pharmacogenomic variants away from wellness advice.

PGS Catalog

Polygenic score metadata and performance, kept for research views.

Known limits: most genome-wide studies are of European ancestry; journal impact metrics are not used; key papers still need manual full-text appraisal. We list these openly because they affect what we can claim.